Company: Ception Therapeutics
Based: Malvern, PA
Investors: Aperture Venture Partners, Essex Woodlands Health Ventures, Greenlight Capital, Individuals, Investor Growth Capital, Lumira Capital Corporation, New Science Ventures, Undisclosed Investor
Scoop: Ception's pipeline includes a late-stage biologic agent (Anti-IL5 MAb) in clinical development for eosinophilic esophagitis and other inflammatory conditions. The company is also working on an oral Anti-TNF drug, an anti-infective program and a novel anti-thrombotic program.